Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine
Abstract
Glioblastoma multiforme (GBM) is a fatal central nervous system tumor without effective treatment. Chemotherapeutic agents are mainstays in the treatment of glioblastoma. However, the effectiveness of these is seriously hindered by poor blood–brain‐barrier (BBB) penetrance and tumor targeting, together with short biological half‐life. Improved chemotherapy is thus urgently needed for GBM. Multifunctional nanoparticle delivery systems offer much promise in overcoming current limitations. Accordingly, a multifunctional biomimetic nanomedicine is developed by functionalizing the surface of red blood cell membranes (RBCms) with angiopep‐2 and loading pH‐sensitive nanoparticles (polymer, doxorubicin (Dox), and lexiscan (Lex)) using the functionalized cell membrane to generate the novel nanomedicine, Ang‐RBCm@NM‐(Dox/Lex). The studies toward orthotopic U87MG human glioblastoma tumor‐bearing nude mice show that the Ang‐RBCm@NM‐(Dox/Lex) nanomedicine has much improved blood circulation time, superb BBB penetration, superior tumor accumulation and retention. Moreover, effective suppression of tumor growth and significantly improved medium survival time are also observed after Ang‐RBCm@NM‐(Dox/Lex) treatment. The results show that this biomimetic nanoplatform can serve as a flexible and powerful system for GBM treatment which can be readily adapted for the treatment of other central nervous system (CNS) disorders.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Angiopep-2-modified red blood cell membrane-camouflaged polymer with DOX and lexiscan has low immunogenicity and systemic toxicity and improves blood cycle time and tumor accumulation in U87MG glioblastoma tumor-bearing nude mice.
“The system with low immunogenicity and systemic toxicity improved blood cycle time and tumor accumulation in U87MG glioblastoma tumor-bearing nude mice.”
From The blood–brain barrier: Structure, regulation and drug delivery (2023) · cites this paper as [198]
The citation lists haven’t been fetched yet
References 55 · Cited by 203
- Authors
- Zou, Y., Liu, Y., Yang, Z., Zhang, D., Lu, Y., Zheng, M., Xue, X., Geng, J., Chung, R., & Shi, B.
- Affiliations
- Henan University (CN)
- Nankai University (CN)
- Sichuan University (CN)
- Macquarie University (AU)
- Corresponding author
- Zheng, Meng
- Shi, Bingyang
- ORCID
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2018-10-16
- Volume
- 30
- Issue
- 51
- Pages
- e1803717-e1803717
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2895971888
- Cited by
- 203
- References
- 55
- Citations by year
- 2026: 4 · 2025: 22 · 2024: 23 · 2023: 31 · 2022: 43 · 2021: 37 · 2020: 28 · 2019: 13 · 2018: 2
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-04-20)
- Open access
- closed
- Locations
- Advanced Materials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (NSFC 31600809, 51803049, U1604177)
- National Health and Medical Research Council (APP1111611)
- China Postdoctoral Science Foundation (2017M620299)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- glioblastoma, biomimetic nanomedicine, Angiopep-2, blood-brain barrier penetration, tumor targeting, pH-responsive nanoparticles, doxorubicin, orthotopic xenograft, brain drug delivery, nanoparticle drug delivery
- MeSH terms
- Animals, Cell Survival, Cell Transformation, Neoplastic, Doxorubicin, Erythrocytes, Glioblastoma, Humans, Peptides, Biomimetic Materials, Cell Line, Tumor, Nanomedicine, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review